Share on :

Asset Summary

Weekly Performance Report for VRTX ETF: Week 50, 2024

Summary: The Weekly started with VRTX ETF opening at $467.33 and closing at $464.12. The ETF showed weakness throughout the Weekly, with the highest price observed at $476.46 and the lowest at $460.05. The underlying asset had a trading range of $16.41 Overall, it was a negative trading Weekly for VRTX ETF, reflecting investor pessimism and market activity.

Change in Closing Price: There was a net decrease of $-3.21 or -0.69% in the closing price from the opening to the closing price over the Weekly.

Volume Analysis: Trading volume for VRTX ETF was 4,128,278 units during Week 50, indicating active market participation and investor interest.

Opening Price: The Weekly started at $467.33.

Highest Price: The highest price observed during the Weekly was $476.46.

Lowest Price: The lowest price observed during the Weekly was $460.05.

Closing Price: The Weekly ended at $464.12.

Asset Performance Metrics and Risk Characteristics:

Understanding asset performance is crucial for evaluating investment quality and making informed decisions. Metrics like trailing return and drawdown provide insights into how an asset has performed over time, its volatility, and the efficiency of its returns relative to risk. Performance indicators help assess the stability, risk, and reward of an investment, allowing investors and portfolio managers to make comparisons and strategize accordingly.

Asset Technical Analysis

Technical analysis involves evaluating an asset's price and volume data to forecast future movements and make informed trading decisions. By using various technical indicators and chart patterns, investors can gain insights into market trends, price momentum, and potential turning points. This section delves into essential technical metrics, including moving averages, pivot points, and other indicators that provide a snapshot of an asset's current technical stance. Analyzing these indicators helps investors identify entry and exit points, assess market sentiment, and refine their trading strategies. Explore the following technical analysis data to understand the asset's performance dynamics and make better-informed decisions.

Moving Averages

Moving Averages are commonly used to smooth out price data and identify trends over a specific period. Here’s a summary of the latest moving averages for various periods:

  • SMA (Simple Moving Average): Reflects the average price over a specific number of periods.
  • EMA (Exponential Moving Average): Gives more weight to recent prices, making it more responsive to new information.
  • WMA (Weighted Moving Average): Assigns a weight to each price, emphasizing more recent prices.
  • WEMA (Weighted Exponential Moving Average): Combines elements of both WMA and EMA for a more responsive moving average.

Advance Your VRTX Trading Now

Elevate your trading strategy with RankMyTrade’s sophisticated tools for VRTX. Our system integrates cutting-edge technology and expert analysis to support your investment goals. Transform your trading strategy now and explore the benefits of advanced trading now!

Take Action Now

Frequently Asked Questions

Vertex is committed to innovation, investing significantly in research to develop groundbreaking therapies for unmet medical needs.

Vertex invests heavily in R&D, focusing on innovative treatments for genetic diseases and other serious conditions.

Vertex has a strong financial outlook due to its successful products and ongoing R&D efforts, though market competition remains a consideration.

Vertex has programs to help patients access their medications, including financial assistance and patient education resources.

Vertex engages with the community through initiatives aimed at supporting patients, advocacy, and scientific research.

Vertex primarily focuses on cystic fibrosis, but also explores therapies for other serious genetic diseases and pain.

Vertex conducts rigorous clinical trials to ensure the safety and efficacy of its therapies before they reach the market.

Vertex was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex faces challenges such as competition from other biotech companies, regulatory hurdles, and the high cost of drug development.

Vertex’s main products include several approved therapies for cystic fibrosis, including Kalydeco, Orkambi, and Trikafta.

Advance Your VRTX Trading Now

Take control of your trading with Rank My Trade Platform. Our platform offers unparalleled analysis and technical support for VRTX, designed to enhance your market performance. Transform your trading strategy now today and experience the difference with our expert tools!

Disclaimers

The information displayed on this site is sourced from third-party providers and is believed to be reliable. RankMyTrade (RMT) has not independently verified this data and does not guarantee its accuracy. The information and calculations provided by RankMyTrade are for educational and informational purposes only and should not be construed as financial or investment advice.

With any investment, your capital is at risk. The value of your portfolio go down as well as up. Past performance is no guarantee of future results. By using this website, you accept our Terms of Service, Privacy Policy, and Payment Agreement.

Market data is provided in near real-time when available, but we do not guarantee its accuracy or timeliness.

Securities products are: Not FDIC insured · Not bank guaranteed · May lose value

Trademarks and logos are the property of their respective owners and do not represent endorsements of any kind. Unless otherwise noted, RankMyTrade and its affiliates are not partners, affiliates, or licensees of these companies.

Supported Assets & ETFs